News
Dr. Campion Achieves First Patient Screened & Enrolled in Phase III SAD Trial
NEW ORLEANS, LA – We are proud to recognize Dr. Caroline Campion and the exceptional research team in New Orleans for achieving a remarkable series of milestones in a Phase 3 clinical trial for Social Anxiety Disorder (SAD). Through seamless coordination, strong patient engagement, and precise operational execution, the site...
150% of Enrollment Goal Achieved Across Four Sites in a Phase 3 Migraine Trial
DelRicht Research is proud to highlight the outstanding performance of our site teams across Atlanta, Gulfport, New Orleans, and Tulsa in a recent Phase 3 clinical trial for migraine. Designed to evaluate the safety and efficacy of an investigational therapy in adults ages 18-70, the study enrolled 400 participants across...
Dr. Patrick Dennis Recognized as Top Enroller in a Phase 2 Hypertension Trial
DelRicht Research is proud to highlight the outstanding performance of Dr. Patrick Dennis and the New Orleans site team at Touro Medical Center in a recent Phase 2 clinical trial evaluating an investigational therapy for adults with uncontrolled hypertension. The study, designed to assess safety and efficacy across 40 U.S....
First to Activate, First to Randomize, and 247% of Goal Achieved in a Phase 2 HS Trial
DelRicht Research is proud to highlight the outstanding performance of our dermatology teams in a recent Phase 2 clinical trial for hidradenitis suppurativa (HS), a chronic and often painful inflammatory skin condition that impacts quality of life for patients worldwide. Across our participating sites in Baton Rouge, LA, and Atlanta,...
Proven Results in Vitiligo Trials: DelRicht Research Delivers Scale, Speed, and Expertise
As dermatology research advances in both innovation and patient demand, DelRicht Research continues to stand out as a trusted partner for sponsors and CROs conducting vitiligo and other pigmentary disorder trials. With 9 vitiligo studies completed in the past five years, and 4 sites ranked as top enrollers across multicenter...
Leading in Gout Research: 39.6% of Participants and 7 of the Top 10 Enrollers in a Phase 3 Trial
DelRicht Research is proud to showcase the outstanding performance of our investigators and site teams in a pivotal US-based Phase 3 trial evaluating treatment for gout, a form of inflammatory arthritis that affects more than 9 million adults in the U.S. Over the course of an 8-month enrollment period, our...
Achieving 310% of Expected Enrollment Goal in a Phase 2/3 AGA Trial
DelRicht Research is proud to spotlight the exceptional performance of our investigators and site teams in a U.S.-based Phase 2/3 clinical trial evaluating treatment for androgenetic alopecia (AGA), a condition that affects millions of males and females and is characterized by progressive loss of terminal hair of the scalp. Over...
FDA Approves Opzelura® for Children Ages 2–11 with Atopic Dermatitis
The U.S. Food and Drug Administration (FDA) has approved Opzelura® (ruxolitinib) cream 1.5%, a topical Janus kinase (JAK) inhibitor developed by Incyte, for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised children two years of age and older whose disease is not well...
Dr. Sean Kerby Achieves First Patient Enrolled in Phase II Gout Trial
GULFPORT, MS – Congratulations to Dr. Sean Kerby and the exceptional team at Gulfport Memorial for screening the very first patient in a Phase 2 clinical trial for gout flares, on the very same day the site was activated. As the first site activated across the entire study, this milestone...
Managing Diagnostic Ambiguity in Psychiatric Research
Why Psychiatric Trials Fail More Often Psychiatric trials are among the most complex in all of clinical research, not because treatments lack potential, but because reliably measuring their effects remains one of the field’s greatest challenges. The stakes are enormous: an estimated 1 in every 8 people (nearly 970 million...
